Advertisement

Drug Safety

, Volume 26, Issue 10, pp 673–683 | Cite as

Do Antiepileptic Drugs Play a Role in Sudden Unexpected Death in Epilepsy?

  • Thaddeus WalczakEmail author
Current Opinion

Abstract

Sudden unexpected death in epilepsy (SUDEP) accounts for approximately 2% of deaths in population-based cohorts of epilepsy, and up to 25% of deaths in cohorts of more severe epilepsy. When it occurs, SUDEP usually follows a generalised tonic-clonic seizure. Unresponsiveness, apnoea, and cardiac arrest occur in SUDEP, rather than the typical gradual recovery. The great majority of tonic-clonic seizures occur without difficulty and how the rare seizure associated with SUDEP differs from others is unknown.

Three mechanisms have been proposed for SUDEP: cardiac arrhythmia, neurogenic pulmonary oedema, and postictal suppression of brainstem respiratory centres leading to central apnoea. Recent studies have found that the incidence of SUDEP increases with the severity of epilepsy in the population studied. The duration of epilepsy, number of tonic-clonic seizures, mental retardation, and simultaneous treatment with more than two antiepileptic drugs are independent risk factors for SUDEP. Some studies have reported that carbamazepine use, carbamazepine toxicity, and frequent, rapid changes in carbamazepine levels, may be associated with SUDEP. Other evidence indicates that carbamazepine could potentially increase the risk for SUDEP by causing arrhythmia or by altering cardiac autonomic function. However, this evidence is tenuous and most studies have not found an association between the use of carbamazepine or any other individual antiepileptic drug and SUDEP.

There is little information regarding antiepileptic drugs other than phenytoin and carbamazepine. The incidence of SUDEP with gabapentin, tiagabine, and lamotrigine clinical development programmes is in the range found in other populations with refractory epilepsy. This suggests that these individual antiepileptic drugs are no more likely to cause SUDEP than antiepileptic drugs in general.

Best current evidence indicates that the risk of SUDEP can be decreased by aggressive treatment of tonic-clonic seizures with as few antiepileptic drugs as necessary to achieve complete control. At present there is no strong reason to avoid any particular antiepileptic drug. Further studies are needed to elucidate the potential role of individual antiepileptic drugs in SUDEP and establish clinical relevance, if any. These studies may be challenging to conduct and interpret because SUDEP is relatively uncommon and large numbers will be necessary to narrow confidence intervals to determine the clinical relevance. Also adjustments will be needed to account for the potent risks associated with other independent factors.

Keywords

Heart Rate Variability Carbamazepine Antiepileptic Drug Tiagabine Epilepsy Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Work supported in part by NIH-NINDS Grant P50:NS16308. The author thanks Dr Ilo Leppik for valuable suggestions and Liliane Dargis for assistance with the manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Bacon GM. On the modes of death in epilepsy. Lancet 1868; I: 555–6CrossRefGoogle Scholar
  2. 2.
    Spratling WP. The causes and manner of death in epilepsy. Med News 1902; 80: 1225–7Google Scholar
  3. 3.
    Jick SS, Cole TB, Mesher RA, et al. Sudden unexplained death in young persons with primary epilepsy. Pharmacoepidemiol Drug Saf 1992; 1: 59–64CrossRefGoogle Scholar
  4. 4.
    Walczak TS, Leppik IE, D’Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001; 56: 519–25PubMedCrossRefGoogle Scholar
  5. 5.
    Ficker DM, So EL, Shen WK, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998; 51: 1270–4PubMedCrossRefGoogle Scholar
  6. 6.
    Nashef L. Sudden unexpected death in epilepsy: terminology and definitions. Epilepsia 1997; 38(11 Suppl.): S6–8PubMedCrossRefGoogle Scholar
  7. 7.
    Leestma JE, Annegers JF, Brodie MJ, et al. Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 1997; 38: 47–55PubMedCrossRefGoogle Scholar
  8. 8.
    Leestma JE, Walczak TS, Hughes JR, et al. A prospective study on sudden unexplained death in epilepsy. Ann Neurol 1989; 26: 195–203PubMedCrossRefGoogle Scholar
  9. 9.
    Leestma JE, Kalelkar MB, Teas SS, et al. Sudden unexpected death associated with seizures: analysis of 66 cases. Epilepsia 1984; 25(1): 84–8PubMedCrossRefGoogle Scholar
  10. 10.
    Terrence CF, Wisotzkey HM, Perper JA. Unexpected, unexplained death in epileptic patients. Neurology 1975 Jun; 25: 594–8PubMedCrossRefGoogle Scholar
  11. 11.
    Nashef L, Garner S, Fish D. Circumstances of death in sudden death in epilepsy: interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 1999; 64: 349–52CrossRefGoogle Scholar
  12. 12.
    Kloster R, Engelskjonm TJ. Sudden unexpected death in epilepsy (SUDEP):a clinical perspective and a search for risk factors. Neurol Neurosurg Psychiatry 1999; 67: 439–444CrossRefGoogle Scholar
  13. 13.
    Langan Y, Nashef L, Sander JW. Sudden unexpected death in epilepsy: a series of witnessed deaths. J Neurol Neurosurg Psychiatry 2000; 68: 211–3PubMedCrossRefGoogle Scholar
  14. 14.
    Terrence CF, Rao GR, Perper JA. Neurogenic pulmonary edema in unexpected, unexplained death of epileptic patients. Ann Neurol 1981; 9: 458–64PubMedCrossRefGoogle Scholar
  15. 15.
    Tennis P, Cole TB, Annegers JF, et al. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 1995; 36: 29–36PubMedCrossRefGoogle Scholar
  16. 16.
    Nilsson L, Farahmand B, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case control study. Lancet 1999 Mar 13; 353: 888–93PubMedCrossRefGoogle Scholar
  17. 17.
    Timmings PL. Sudden unexpected death in epilepsy: is carbamazepine implicated? Seizure 1998; 7: 289–91PubMedCrossRefGoogle Scholar
  18. 18.
    Nashef L, Fish DR, Garner S, et al. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia 1995; 36: 1187–94PubMedCrossRefGoogle Scholar
  19. 19.
    Nashef L, Fish DR, Sander JW, et al. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 1995; 58: 462–4PubMedCrossRefGoogle Scholar
  20. 20.
    Neurontin. In: Physicians Desk reference. 50th ed. Montvale (NJ): Med Econ 1996, 1924Google Scholar
  21. 21.
    Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36(6 Suppl.): S10–S3PubMedCrossRefGoogle Scholar
  22. 22.
    Annegers JF, Coan SP, Hauser WA, et al. Epilepsy, and vagal nerve stimulation by the NCP system, all cause mortality and sudden unexpected, unexplained death. Epilepsia 2000; 41: 549–53PubMedCrossRefGoogle Scholar
  23. 23.
    Dasheiff RM, Dickinson LJ. Sudden unexpected death of epileptic patients due to cardiac arrhythmia after seizure. Arch Neurol 1986; 43: 194–6PubMedCrossRefGoogle Scholar
  24. 24.
    Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46: 45–50PubMedCrossRefGoogle Scholar
  25. 25.
    Hirsch CS, Martin DL. Unexpected death in young epileptics. Neurology 1971 Jul; 21: 682–90PubMedCrossRefGoogle Scholar
  26. 26.
    Jay GW, Leestma JE. Sudden death in epilepsy. Acta Neurol Scand 1981; 63(82 Suppl.): 1–66Google Scholar
  27. 27.
    Lathers CM, Schrader PL, Boggs J. Synchronization of cardiac autonomic neural discharge with epileptogenic activity: the lockstep phenomenon. Electroencephalogr Clin Neurophysiol 1987; 67: 247–59PubMedCrossRefGoogle Scholar
  28. 28.
    Keilson MJ, Hauser WA, Magrill JP, et al. ECG abnormalities in patients with epilepsy. Neurology 1987; 37: 1624–6PubMedCrossRefGoogle Scholar
  29. 29.
    Blumhardt LD, Smith PEM, Owen L. Electrocardiographic accompaniments of temporal lobe epileptic seizures. Lancet 1986 May; 10: 1051–5CrossRefGoogle Scholar
  30. 30.
    Johnston SC, Horn JK, Valnete J, et al. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 1995; 37: 531–7PubMedCrossRefGoogle Scholar
  31. 31.
    Johnston SC, Siedenberg R, Min J, et al. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 1997; 42: 588–94PubMedCrossRefGoogle Scholar
  32. 32.
    Archibald RB, Armstrong JD. Recurrent postictal pulmonary edema. Postgrad Med 1978; 63: 210–3PubMedGoogle Scholar
  33. 33.
    Reynolds RW. Pulmonary edema as a consequence of hypothalamic lesions in rats. Science 1963; 141: 930–2PubMedCrossRefGoogle Scholar
  34. 34.
    Simon RP. Epileptic sudden death: animal models. Epilepsia 1997; 38(11 Suppl.): S35–7PubMedCrossRefGoogle Scholar
  35. 35.
    Epilepsy and sudden death: proceedings of an international workshop [discussion]. Epilepsia 1997; 38 (11 Suppl): S57–S59Google Scholar
  36. 36.
    Nashef L, Walker F, Allen P, et al. Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy. J Neurol Neurosurg Psychiatry 1996; 60: 297–300PubMedCrossRefGoogle Scholar
  37. 37.
    Bird JM, Dembny KAT, Sandeman D, et al. Sudden unexplained death in epilepsy: an intracranially monitored case. Epilepsia 1997; 38(11 Suppl.): 52–6CrossRefGoogle Scholar
  38. 38.
    So EL, Sam MC, Lagerlund TL. Postictal central apnea as a cause of SUDEP: evidence from a near-SUDEP incident. Epilepsia 1999; 41: 1494–7CrossRefGoogle Scholar
  39. 39.
    George JR, Davis GG. Comparison of anti-epileptic drug levels in different cases of sudden death. J Forensic Sci 1998; 43: 598–603PubMedGoogle Scholar
  40. 40.
    Opeskin K, Burke MP, Cordner SM, et al. Comparison of antiepileptic drug levels in sudden unexpected deaths in epilepsy with deaths from other causes. Epilepsia 1999; 40(12): 1795–8PubMedCrossRefGoogle Scholar
  41. 41.
    Tomson T, Skold AC, Holmgen P, et al. Postmortem changes in blood concentrations of phenytoin and carbamazepine: an experimental study. Ther Drug Monit 1998; 20: 309–12PubMedCrossRefGoogle Scholar
  42. 42.
    Nilsson L, Bergman U, Diwan V, et al. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia 2001; 42(5): 667–73PubMedCrossRefGoogle Scholar
  43. 43.
    Tomson T, Kenneback G. Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia 1997; 38(11 Suppl.): S48–51PubMedCrossRefGoogle Scholar
  44. 44.
    Durelli L, Mutani R, Sechi GP, et al. Cardiac side effects of phenytoin and carbamazepine. Arch Neurol 1985; 42: 1067–8PubMedCrossRefGoogle Scholar
  45. 45.
    Kasarkis EJ, Kuo CS, Berger R, et al. Carbamazepine-induced cardiac dysfunction: characterization of two distinct clinical syndromes. Arch Intern Med 1992; 152: 186–91CrossRefGoogle Scholar
  46. 46.
    Kennebäck G, Bergfeldt L, Tomson T, et al. Carbamazepine induced bradycardia: a problem in general or only in susceptible patients? A 24 hour long term ECG study. Epilepsy Res 1992; 13: 141–5PubMedCrossRefGoogle Scholar
  47. 47.
    Matteoli S, Trappolini M, Curione M, et al. Effeti della carbamazepine sull’ eccitoconduzione cariaca in soggetti giovani: studio seriato con ECG-dinamico. G Ital Cardiol 1994; 24: 391–7PubMedGoogle Scholar
  48. 48.
    Massettani R, Strata G, Galli R, et al. Alteration of cardiac function in patients with temporal lobe epilepsy: different roles of EEG-ECG monitoring and spectral analysis of RR variability. Epilepsia 1997; 38: 363–9CrossRefGoogle Scholar
  49. 49.
    Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000; 41: 1342–5PubMedCrossRefGoogle Scholar
  50. 50.
    Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55: 722–4PubMedCrossRefGoogle Scholar
  51. 51.
    Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999; 35: 147–53PubMedCrossRefGoogle Scholar
  52. 52.
    Ramsay RE, Uthman B, Leppik IE, et al. The tolerability and safety of valproate sodium injection given as an intravenous infusion. J Epilepsy 1997; 10: 187–93CrossRefGoogle Scholar
  53. 53.
    Isojarvi JI, Ansakkorpi H, Suominen K, et al. Interictal cardiovascular autonomic responses in patients with epilepsy. Epilepsia 1998; 39: 420–6PubMedCrossRefGoogle Scholar
  54. 54.
    Ansakorpi H, Korpelainen JT, Suominen K, et al. Interictal cardiovascular autonomic responses in patients with temporal lobe epilepsy. Epilepsia 2000; 41: 42–7PubMedCrossRefGoogle Scholar
  55. 55.
    Devinsky O, Perrine K, Theodore WH. Interictal autonomic nervous system function in patients with epilepsy. Epilepsia 1994; 35: 199–204PubMedCrossRefGoogle Scholar
  56. 56.
    Tomson T, Ericson M, Ihrman C, et al. Heart rate variability in patients with epilepsy. Epilepsy Res 1998; 30: 77–83PubMedCrossRefGoogle Scholar
  57. 57.
    Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93: 1043–65Google Scholar
  58. 58.
    Sleight P, La Rovere MT, Mortara A, et al. Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of baroreflex gain? Clin Sci 1995; 88: 103–9PubMedGoogle Scholar
  59. 59.
    Druschky A, Hilz MJ, Hopp P, et al. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [123I] metaiodobenzylguanidine-SPECT. Brain 2001; 124: 2372–82PubMedCrossRefGoogle Scholar
  60. 60.
    Hennessy MJ, Tighe MG, Binne CD, et al. Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep. Neurology 2001; 57: 1650–4PubMedCrossRefGoogle Scholar
  61. 61.
    Kenneback G, Ericson M, Tomson T, et al. Changes in arrhythmia profile and heart rate variability during abrupt withdrawal of antiepileptic drugs: implications for sudden death. Seizure 1997; 6: 369–75PubMedCrossRefGoogle Scholar
  62. 62.
    Moss G, Stein AA. Cerebral etiology of the acute respiratory distress syndrome: diphenylhydantoin prophylaxis. J Trauma 1975; 15: 39–41PubMedCrossRefGoogle Scholar
  63. 63.
    Lathers CM, Schraeder PL. Autonomic dysfunction in epilepsy: characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 1982; 23: 633–47PubMedCrossRefGoogle Scholar
  64. 64.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9PubMedCrossRefGoogle Scholar
  65. 65.
    Engel Jr J, Van Ness PC, Rasmussen TB, et al. Outcome with respect to epileptic seizures. In: Engel Jr J, editor. Surgical treatment of the epilepsies. 2nd ed. New York: Raven Press Ltd, 1993Google Scholar
  66. 66.
    Wiebe S, Blume WT, Girvin JP, et al. for the Effectiveness and Efficiency of Surgery For Temporal Lobe Epilepsy Study Group. A randomized controlled trial of surgery for temporallobe epilepsy. N Engl J Med 2001; 345: 311–8PubMedCrossRefGoogle Scholar
  67. 67.
    Handforth A, DeGiorgio CM, Schacter SC, et al. Vagal nerve stimulation therapy for partial onset seizures: a randomized active control trial. Neurology 1998; 51: 48–55PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.MINCEP® Epilepsy Care, Minneapolis, Minnesota, USA, and Department of NeurologyUniversity of MinnesotaMinneapolisUSA

Personalised recommendations